EACH RETINOID MOLECULE IN ZYMBILAN® CREAM IS SURROUNDED BY A UNIQUE NANO-ENCAPSULATION TECHNOLOGY

RetileX-A®-PRO: The novel, next-generation retinoid

The proprietary technology utilised in RetileX-A®-PRO creates an ‘envelope’ around each retinoid molecule in Zymbilan® cream, protecting these molecules from light and oxidation and allowing them to penetrate the psoriatic epidermal cells. These molecules are absorbed deeper into the skin, where they are then released and can exert their full efficacy to normalise skin turnover and expression.

RetileX-A®-PRO was developed by Pharma Medico in Scandinavia as a next-generation retinoid and is backed by more than 30 years of research. It has been proven effective in addressing a number of inflammatory skin conditions, including: Scalp psoriasis, chronic plaque psoriasis, inverse or flexural psoriasis, pustular psoriasis, guttate psoriasis, and conditions like dermatitis, eczema, pityriasis rosea, and other fungal infections.

Zymbilan®-PSO cream with RetileX-A®-PRO rebalances and revives skin by:

• Suppressing the uncontrolled proliferation of keratinocytes and acanthosis which lead to thickening of the outermost layer of the skin (stratum corneum).
• Normalising the differentiation of keratinocytes and epidermal hyperkeratosis to alleviate psoriatic lesions.
• Subsiding inflammatory reactions and cytokine production in psoriatic lesions.
• Controlling abnormal blood vessel formation (Neovascularisation).
• Possessing anabolic effects on skin proteoglycans and other matrix components to alleviate Epidermal Dysglycania (EDG) in psoriatic lesions.

RetileX-A®-PRO
High concentration nano-encapsulated retinoid

Ingredient List (full)
Aqua, aloe barbadensis leaf juice, glycerin, caprylic/capric triglyceride, decyl oleate, cetyl alcohol, stearyl alcohol, carthamus tinctorius seed oil, candelilla/jojoba/rice bran polyglyceryl-3 esters, glyceryl stearate, cyclodextrin, sodium pca, sodium stearoyl lactylate, cetearyl alcohol, phenoxyethanol, ethyl olivate, ethylhexylglycerin, retinyl palmitate, carbomer, olus oil, benzoic acid, dehydroacetic acid, sodium lactate, sodium phytate, tocopheryl acetate, sodium hydroxide, sodium carboxymethyl betaglucan, tocopherol, beta-sitosterol, olea europaea leaf extract, carnosine, lactic acid, alcohol.

Precautions

• Zymbilan®-PSO cream is not recommended for the treatment of unstable or erythrodermic psoriasis.
• Patients under treatment with Zymbilan®-PSO cream need to consult with their physician before undergoing phototherapy.
• During the first months of treatment with Zymbilan®-PSO cream, individuals are advised to avoid excessive sun exposure and use sunscreen of at least SPF 15 during exposure.
• Avoid applying Zymbilan®-PSO cream around eyes and on genital areas.
• If any skin reactions connected with the application of Zymbilan®-PSO cream occur and do not subside with decreasing the frequency of use, treatment should be discontinued.

Directions
Apply Zymbilan®-PSO cream to psoriatic skin lesions once a day in the evening for the first 2 weeks. If tolerated, then use Zymbilian®-PSO twice a day thereafter (one in the morning, and once in the evening).

Apply Zymbilan®-PSO cream to psoriatic skin lesions after washing the lesions with a gentle cleanser. Distribute the cream to cover the surface of each lesion and gently pat until absorbed. Allow time between applying Zymbilan®-PSO cream and using other products.

The duration of treatment varies in different cases depending on the severity and treatment response of the lesions. Patients with a chronic condition are recommended to consider long-term maintenance therapy with Zymbilan®-PSO cream.